To evaluate this hypothesis, we used a well-established and clinically relevant model of acute myeloid leukaemia (AML) driven by expression of the fusion oncogene MLL-AF9 (MA9)9, 10. This evidence concerns the gene KMT2A and acute myeloid leukemia.